WINSTON-SALEM, N.C.--(BUSINESS WIRE)--Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing a new class of drugs known as NNR Therapeutics (TM), today announced that it will report financial results for the fourth quarter and year ended December 31, 2008 on Thursday, February 12, 2009, after the U.S. financial markets close.
